With over 40,000 citations supporting the validity of their methodology, biotx. ai offers a proven method to ensure success in clinical trials. Their real-time analysis has demonstrated extraordinary accuracy in predicting COVID-19 drug trial outcomes, enabling the identification of effective treatments and even the discovery of new ones.

For severe cases of COVID-19, biotx. ai has successfully repurposed drugs such as Anakinra, Tocilizumab, Dexamethasone, and Baricitinib, among others. They have also made significant breakthroughs in various diseases, including cardiovascular and thrombotic disease, cardioembolic stroke, non-alcoholic steatohepatitis, heart failure, and cardiometabolic disease.

With their platform and vast biobank, which includes over 28,500 drugs and 2 million human genomes, biotx. ai is at the forefront of enabling scalable causal modeling. Notably, their success stories include renowned biotech and pharma companies, such as Immungentics, Alfa Intes, and Eternygen.

With their invaluable expertise, biotx. ai is revolutionizing the field of drug discovery and empowering the future of healthcare